Humana (NYSE:HUM) Shares Gap Down to $404.52

Humana Inc. (NYSE:HUM) gapped down before the market opened on Wednesday . The stock had previously closed at $404.52, but opened at $366.01. Humana shares last traded at $376.26, with a volume of 714,900 shares.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Bank of America raised their target price on Humana from $342.00 to $376.00 and gave the stock a “neutral” rating in a research note on Monday, May 20th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $360.00 target price on shares of Humana in a research note on Tuesday, July 23rd. TD Cowen raised their target price on Humana from $396.00 to $407.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Jefferies Financial Group reduced their price objective on Humana from $411.00 to $381.00 and set a “buy” rating for the company in a research note on Monday, April 22nd. Finally, Baird R W raised Humana to a “hold” rating in a research note on Thursday, May 30th. Fourteen analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $403.55.

Humana Stock Up 1.3 %

The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67. The stock has a fifty day moving average of $367.62 and a 200 day moving average of $347.54. The firm has a market capitalization of $43.82 billion, a P/E ratio of 22.33, a price-to-earnings-growth ratio of 2.09 and a beta of 0.51.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. Humana had a return on equity of 16.17% and a net margin of 1.53%. The business had revenue of $29.54 billion during the quarter, compared to the consensus estimate of $28.52 billion. During the same period last year, the business posted $8.94 earnings per share. The business’s revenue for the quarter was up 10.4% on a year-over-year basis. On average, research analysts anticipate that Humana Inc. will post 16.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Humana

Several hedge funds have recently made changes to their positions in HUM. Assenagon Asset Management S.A. grew its position in shares of Humana by 2.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 4,250 shares of the insurance provider’s stock valued at $1,946,000 after purchasing an additional 109 shares in the last quarter. Trust Point Inc. purchased a new position in Humana during the fourth quarter worth about $505,000. International Assets Investment Management LLC grew its position in Humana by 32,648.4% during the fourth quarter. International Assets Investment Management LLC now owns 134,596 shares of the insurance provider’s stock worth $61,619,000 after buying an additional 134,185 shares in the last quarter. Capital Insight Partners LLC grew its position in Humana by 9.5% during the fourth quarter. Capital Insight Partners LLC now owns 1,607 shares of the insurance provider’s stock worth $736,000 after buying an additional 140 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC grew its position in Humana by 36.6% during the fourth quarter. Prime Capital Investment Advisors LLC now owns 1,130 shares of the insurance provider’s stock worth $517,000 after buying an additional 303 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.